Nippon Shinyaku Co., Ltd.

Nippon Shinyaku Co., Ltd.

NPNKF

$23.50

Updated: 23/09/2026, 06:32:26

Market Cap
$1.58B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
JP
Stock valuation chart
One-year closing share-price history for NPNKF
Company Profile

Nippon Shinyaku Co., Ltd., founded in Kyoto, Japan, in 1911, operates globally as a developer, manufacturer, and distributor of pharmaceutical products and functional foods. The company is organized into two primary divisions: Pharmaceuticals and Functional Food. Within its Pharmaceutical division, Nippon Shinyaku offers an extensive range of medications to markets across Japan, Switzerland, and other international territories. These therapeutic solutions address diverse medical challenges such as urological disorders, inflammatory and allergic conditions, hematologic malignancies, cardiovascular and metabolic diseases, and gastrointestinal ailments. Key pharmaceutical offerings include Zalutia and Eviprostat for benign prostatic urinary issues; Bladderon for frequent urination; Estracyt for prostate cancer; and Cialis for erectile dysfunction. Its oncology and hematology portfolio further encompasses Vidaza for myelodysplastic syndrome; Cylocide for solid tumors and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company also provides Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for the management of cancer and chronic pain. Beyond its existing product lines, Nippon Shinyaku actively invests in the research, development, and commercialization of new treatments within gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment delivers a variety of health-oriented products, including health food ingredients, preservatives, protein preparations, supplements, and a selection of spices and condiments.

USD
OTC
CEO: Toru Nakai
Employees: 2,309
https://www.nippon-shinyaku.co.jp
Asset Summaries
Latest generated summaries for NPNKF

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for NPNKF.
Share price
$23.50
Market cap
$1.58B
Exchange
OTC
Currency
USD
CEO
Toru Nakai
Employees
2,309
IPO date
03/09/2021
Beta
-0.324
Last dividend
$0.00
Day range
$23.50 – $32.75
52-week range
$21.00 – $38.01
1-day performance
0.00%
1-year performance
11.90%
Current drawdown (1Y)
-38.17%
CIK
N/A
CUSIP
N/A
ISIN
JP3717600005
Created
07/12/2025, 05:29:37
Last update
23/09/2026, 06:32:26

Track Nippon Shinyaku Co., Ltd. with an AI analyst

See which prediction-market events move NPNKF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to NPNKF from your Railway `news_articles` table.

No news found for this symbol.